The KD-CAAP Recruitment Window is now
CLOSED!
Number of Recruited Participants: 103
Thank you to our participating sites for all your ongoing hard work and support on the trial in helping us achieve this milestone.
Last Updated: 01-Aug-2024 15:00 BST
Kawasaki Disease Coronary Artery Aneurysm Prevention trial
A multi-centre, randomised, open-label, blinded endpoint assessed, trial of corticosteroids plus intravenous immunoglobulin (IVIG) and aspirin, versus IVIG and aspirin for prevention of coronary artery aneurysms (CAA) in Kawasaki disease (KD)
Welcome to KD-CAAP
The website has been designed to provide information, news and updates on the KD-CAAP trial to participants, parents, carers, the public and trial collaborators.
KD-CAAP is aiming to determine whether adding immediate corticosteroid treatment to standard of care IVIG and aspirin will reduce coronary artery aneurysm (CAA) rates in unselected Kawasaki Disease (KD) patients across Europe compared with IVIG and aspirin alone.
Follow the links below or use the menu bar at the top of the page to find out more about the trial and its network collaboration.
Find out more about:
This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No.777389.
The Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.